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Summary
Objective: Glucosamine has been previously shown to suppress cartilage aggrecan catabolism in explant cultures. We determined the effect
of glucosamine on ADAMTS5 (a disintegrin-like and metalloprotease domain (reprolysin type) with thrombospondin type-1 motifs 5), a major
aggrecanase in osteoarthritis, and investigated a potential mechanism underlying the observed effects.
Design: HEK293F and CHO-K1 cells transiently transfected with ADAMTS5 cDNA were treated with glucosamine or the related hexosamine
mannosamine. Glucosamine effects on FURIN transcription were determined by quantitative RT-PCR. Effects on furin-mediated processing of
ADAMTS5 zymogen, and aggrecan processing by glucosamine-treated cells, were determined by western blotting. Post-translational modi-
ﬁcation of furin and N-glycan deﬁcient furin mutants generated by site-directed mutagenesis was analyzed by western blotting, and the mu-
tants were evaluated for their ADAMTS5 processing ability in furin-deﬁcient CHO-RPE.40 cells.
Results: Ten mM glucosamine and 5e10 mM mannosamine reduced excision of the ADAMTS5 propeptide, indicating interference with the
propeptide excision mechanism, although mannosamine compromised cell viability at these doses. Although glucosamine had no effect on
furin mRNA levels, western blot of furin from glucosamine-treated cells suggested altered post-translational modiﬁcation. Glucosamine treat-
ment led to decreased glycosylation of cellular furin, with reduced furin autoactivation as the consequence. Recombinant furin treated with
peptide N-glycanase F had reduced activity against a synthetic peptide substrate. Indeed, site-directed mutagenesis of two furin N-glycosyl-
ation sites, Asn387 and Asn440, abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deﬁcient cells.
Conclusions: Ten mM glucosamine reduces excision of the ADAMTS5 propeptide via interference with post-translational modiﬁcation of furin
and leads to reduced aggrecanase activity of ADAMTS5.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a common disorder characterized by
loss of articular cartilage as a result of degenerative
changes in the joint. An early phenomenon in cartilage deg-
radation is proteolytic loss of aggrecan, which forms giant
aggregates with hyaluronan in the extracellular matrix
(ECM)1. These aggregates bind water, and are constrained
by a collagen network, which gives cartilage its compress-
ibility. Aggrecan proteolysis diminishes cartilage compress-
ibility and exposes collagen and other cartilage ECM
proteins to degradation, thereby setting in motion a vicious
cycle of cartilage breakdown2. Two secreted metallopro-
teases, ADAMTS4 and ADAMTS5 (a disintegrin-like and
metalloprotease domain (reprolysin type) with thrombo-
spondin type-1 motifs), referred to as aggrecanases, cleave
aggrecan efﬁciently and are implicated as key mediators of
OA3,4. Therefore, inhibition of these proteases, such as by
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455biosynthetic interference, is of signiﬁcant therapeutic inter-
est5. ADAMTS5, also known as aggrecanase-2, has at-
tracted considerable interest as a target in OA5,6 since
mice with a targeted deletion of Adamts5 are resistant to
both immune and mechanically induced arthritis7,8.
ADAMTS5 is synthesized as a zymogen (proADAMTS5)
which undergoes proteolytic excision of its propeptide by pro-
protein convertases (PCs) such as furin and PACE49,10.
ADAMTS4 and ADAMTS5 each require propeptide excision
for proteolytic activity, but they are activated somewhat differ-
ently. ADAMTS4 is processed intracellularly11, whereas
ADAMTS5 is processed extracellularly by furin and/or other
PCs. ADAMTS4 and ADAMTS5 zymogens may also be de-
posited in cartilage ECM, where they are activated by se-
creted PCs such as PACE410. Both furin and PACE4,
which activate ADAMTS5 efﬁciently, cleave the consensus
cleavage site, RRRR261Y, which is present at the junction
of the ADAMTS5 propeptide and catalytic domain9,10,12.
The hexosamines glucosamine and mannosamine were
previously shown to suppress aggrecan catabolism in carti-
lage explant cultures13e19. Both hexosamines can interfere
with N-glycosylation20,21, and mannosamine is a recognized
inhibitor of glycosylphospatidyl-inositol (GPI) anchor forma-
tion14e19. The effects of hexosamines on ADAMTS4
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tigated at the molecular level. C-terminal processing of
furin-activated ADAMTS4 by a GPI-anchored metallopro-
tease located at the cell surface was inhibited by mannos-
amine15,22. Treatment of cells with hexosamines also led
to a prevalence of unprocessed ADAMTS4 zymogen15.
ADAMTS4 lacks N-linked glycans4, so the observed effects
could not be attributed to inhibition of its N-glycosylation by
hexosamines. These published observations led us to ex-
amine the effects of glucosamine on ADAMTS5 activity,
and to elucidate the molecular mechanisms of the observed
effects. Unlike ADAMTS4, ADAMTS5 is N-glycosylated and
does not bind to the cell surface, but has been shown to re-
side in the ECM23,24. In cultured cells, which make little
ECM, such as HEK293F cells, ADAMTS5 is present in
the conditioned medium (CM)9. Here, we show that hexos-
amine treatment of cells interferes with the activation of
ADAMTS5 through an indirect mechanism involving the
loss of furin activity. These ﬁndings provide one possible
explanation for previously observed suppressive effects of
glucosamine on cartilage catabolism and are thus relevant
to OA biochemistry.Materials and methodsCELL CULTURE AND TREATMENTSHEK293F cells and CHO-K1 cells (ATCC, Manassus, VA) were cultured
in Dulbecco’s Modiﬁed Eagles Medium (DMEM, high glucose) supplemented
with 10% FBS and antibiotics. Furin-deﬁcient CHO-RPE.40 cells25 were cul-
tured in Ham’s F12 medium (high glucose) supplemented with 10% FBS and
antibiotics.EXPRESSION PLASMIDS AND SITE-DIRECTED MUTAGENESISConstructs for expression of full-length human ADAMTS5 and the propep-
tide and catalytic domain of human ADAMTS5 (ADAMTS5 Pro-Cat) were
previously described9 (Fig. 1). Asn residues within two of three consensus
N-linked glycosylation sites in furin (GenBank accession no. NP_002560)
were mutated singly (Asn387, Asn440), or in combination (Asn387þ440), by re-
placement with Gln using site-directed mutagenesis (Quikchange site-di-
rected mutagenesis kit, Stratagene, La Jolla, CA). The mutations were
introduced into full-length untagged human furin and a furin construct withFig. 1. ADAMTS5 constructs used in the analysis of glucosamine effe
predicted molecular weights of the relevant protein species, N-linked gly
various modules is at thean N-terminal FLAG tag introduced immediately downstream of the furin au-
toactivation site26.
Expression plasmids were transiently transfected into HEK293F, CHO-K1
and CHO-RPE.40 cells using FUGENE6 (Roche Diagnostics, Indianapolis,
IN). HEK293F and CHO-K1 cells were treated with glucosamineeHCl (neu-
tralized to pH 7.4 before use) or mannosamine (SigmaeAldrich, St. Louis,
MO). Before treatment, cells were transferred to serum-free DMEM contain-
ing 5 mM glucose for 3e5 h13. Fresh medium containing each compound in
a range of concentrations was added to cells. CM was collected, and cells
were harvested in phosphate buffered saline after 24 h or 48 h followed
by lysis in 1% Triton X-100, 10 mM Tris.HCl, pH 7.6 containing complete
protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). In some
experiments, HEK293F and CHO-RPE.40 cells were transfected (or
co-transfected) with furin (either wildtype or Asn/Gln mutants) and/or
ADAMTS5 Pro-Cat plasmid. As a control, empty vector used for furin cloning
(pCI-Neo, Promega, Madison, WI) was co-transfected with ADAMTS5 Pro-
Cat in CHO-RPE.40 cells. Serum-free media and cell lysates were collected
after 48 h and processed as described above.QUANTITATIVE RT-PCRHEK293F cells were treated with glucosamine and harvested after 48 h
as described above. Total RNA was extracted using QIAGEN complete
RNA isolation kit (QIAGEN, Valencia, CA). RNA concentration and purity
were determined with a NanoDrop (ND-100) spectrophotometer (Nanodrop
Technologies, Wilmington, DE). All RNA samples used had an A260/280 ra-
tio of >1.8. Two mg of total RNA per condition was reverse transcribed to
cDNA in a total volume of 20 ml using the Superscript III kit (Invitrogen, Carls-
bad, CA). For quantitative PCR, the FURIN primers 50-CAGCGGTGGCCAA-
CAGTGTG-30 (forward) 50-GCGGGCGGTGAGGCGACA-30 (reverse) and
18s ribosomal RNA primers, 50-GGGAGGTAGTGACGAAAAATAACAAT-30
(forward), 50-TTGCCCTCCAATGGATCCT-30 (reverse) were used. SYBR-
Green (Applied Biosystems, Foster City, CA) incorporation was detected us-
ing an iCycler (Bio-Rad. Hercules, CA) and relative levels of FURIN mRNA
were quantitated using the DDct method as per manufacturer’s protocol.WESTERN BLOTTING, ENZYMATIC DEGLYCOSYLATION OF
FURIN, AND DETERMINATION OF AGGRECANASE ACTIVITYFor western blots, CM and cell lysate were electrophoresed by reducing
SDS-PAGE in 6%or 7.5%gels prior to electroblotting to polyvinylidene ﬂuoride
membrane (Millipore, Billerica, MA). PeptideN-glycosidase F (PNGaseF, New
England Biolabs, Ipswich, MA) treatment was carried out as per manufactur-
er’s instructions following reduction of the sample. ADAMTS5wasdetectedus-
ing rabbit polyclonal antibody RP2 (recognizing the propeptide) (Triple Point
Biologics, Forest Grove, OR)9 or anti-myc mouse monoclonal antibody 9E10
(SigmaeAldrich, St. Louis, MO). Anti-GAPDH mouse monoclonal antibody
(Chemicon, Temecula, CA) was used to detect intracellular and extracellular
GAPDH to ensure equivalent protein loading. Anti-furin mouse monoclonalcts. Domain organization of ADAMTS5 and ADAMTS5 Pro-Cat,
cosylation site and furin processing site are shown. The key to the
bottom of the ﬁgure.
Fig. 2. ADAMTS5 activation is inhibited by glucosamine treatment. A. Treatment of HEK293F cells transiently transfected with ADAMTS5 us-
ing 5 mM or 10 mM glucosamine results in increased uncleaved zymogen (top two panels) and decreased processed propeptide (Pro, second
panel from the bottom). Western blotting with anti-GAPDH (bottom panel) was used to indicate sample loading. B. Quantitation of the effects of
10 mM glucosamine on the levels of ADAMTS5 zymogen and cleaved propeptide from three independent experiments shows a statistically
signiﬁcant effect of glucosamine on zymogen cleavage (*P< 0.05; Student’s t test, error bars represent S.E.M.). C. Treatment with 10 mM glu-
cosamine results in loss of aggrecanase activity in the medium of ADAMTS5-transfected HEK293F cells. The top two panels illustrate reduced
zymogen processing, whereas the anti-NITEGE373 immunoblot (second panel from the bottom) shows reduced aggrecanase activity in
medium of glucosamine-treated cells.
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Biochemicals, San Diego, CA) was used for detection of endogenous and un-
tagged furin, whereas mouse anti-FLAG M1 or M2 monoclonal antibody and
rabbit anti-FLAG polyclonal antibody were used for detection of FLAG-tagged
furin (FLAGantibodies fromSigmaeAldrich, St. Louis, MO). Anti-FLAGM2an-
tibody recognizes theFLAG tagat any positionwithin the protein, whereas anti-
FLAG M1 preferentially recognizes a FLAG tag at the free N-terminus. Anti-
body binding was detected by enhanced chemiluminescence (ECL, GE
Healthcare, Piscataway, NJ). For detection of endogenous furin, ECL-Plus
(GE Healthcare, Piscataway, NJ) was utilized. Intensity of relevant bands
was quantitated using IMAGE J software (NIH, Bethesda, MD). A type 1
(paired), 2-tailed Student’s t test was used to determine whether the normal-
ized data obtained from the IMAGE J software was statistically signiﬁcant
(P  0.05) between the control and test group, Gaussian distribution was
assumed.ADAMTS5cleavageof aggrecanat theGlu373eAla374peptidebondwasdeter-
mined using a modiﬁcation of a previously described experimental procedure9.
HEK293F cells were transfected with full-length ADAMTS5 followed by the addi-
tion of serum-freemediumwith or without 10 mMglucosamine. CMwas collected
after 48 h. Fifty ml of CM from control (untransfected) or from each respective
ADAMTS5 transfection was incubated with 4 mg bovine aggrecan (SigmaeAl-
drich) for 16 h at 37C in the presence of an EDTA-free protease inhibitor cocktail
(Roche). Each reaction was heat-inactivated (5 min, 100C), cooled on ice, and
aggrecanwasdeglycosylatedwithprotease-freechondroitinaseABC,keratanase
I and keratanase II (Seikagaku, Tokyo, Japan) at 37C for 2 h. Western blotting
wasperformedusing theanti-NITEGEaggrecanneo-epitopeantibody that specif-
ically detects cleavage at the Glu373eAla374 peptide bond (kindly provided by Dr.
John Sandy, Rush University Medical Center). ADAMTS5 zymogen, mature
ADAMTS5 and ADAMTS5 propeptide in the CM were detected by western blot.
Anti-GAPDH was used as a control to demonstrate comparable cell numbers.
Fig. 3. Effect of mannosamine on ADAMTS5 propeptide process-
ing, and cell viability after glucosamine and mannosamine treat-
ment with various doses. A. Treatment of ADAMTS5-transfected
HEK293F cells with 5 mM, and 10 mM mannosamine resulted in
a dose-dependent inhibition of ADAMTS5 zymogen processing.
GAPDH western blot suggests decreased cell numbers with
5e10 mM mannosamine (bottom panel). B. Trypan blue exclusion
assay shows that 5e10 mM mannosamine and 25 mM glucos-
amine, but not 10 mM glucosamine had a signiﬁcant decrease in
cell viability (the data are presented as the meanS.D. of 10 cell
counts from duplicate and control hexosamine-treated cultures).
Fig. 4. Glucosamine affects post-translational modiﬁcation of furin.
A. Furin mRNA levels in HEK293F cells treated with 10 mM glucos-
amine were similar to those of untreated cells. 18s ribosomal RNA
levels were used for normalization of furin mRNA. The data are pre-
sented as the meanS.D. from three independent experiments. B.
Treatment with 5 mM and 10 mM glucosamine alters electropho-
retic migration of furin in HEK293F cells. The major furin species
seen with 5 mM and 10 mM glucosamine treatments corresponds
in size to active furin.
458 D. R. McCulloch et al.: Glucosamine and aggrecanase activationFLUOROGENIC SUBSTRATE ASSAY OF FURIN ACTIVITYRecombinant human furin (rhFurin, purity >95%) was purchased from
R&D systems (Minneapolis, MN). Fifty or 100 ng of rhFurin per reaction
was treated with PNGaseF (New England Biolabs) or with heat-inactivated
PNGaseF (100C, 5 min) as a control in HEPES buffer (100 mM HEPES,
0.5% Triton X-100, 1 mM CaCl2, 1 mM b-mercaptoethanol, pH 7.5) for 2 h
at 37C. Substrate cleavage was measured by the liberation of amino-4-
methylcoumarin (AMC) from Boc-RVRR-AMC (ﬁnal concentration 100 mM,
Biomol, Plymouth Meeting, PA) in 100 ml HEPES buffer, pH 7.5. Fluores-
cence was measured every minute (total 90 min) on a Victor 2 1420 Multila-
bel Counter ﬂuorescent plate reader (Perkin Elmer, Waltham, MA) with
excitation/emission wavelength of 355/460 nm respectively. Each assay
was run in triplicate in two separate assays in 96-well plates. The extinction
co-efﬁcient (3) of AMC was determined to be 17.3 mm1 cm1 using an
evenly spaced standard curve (range 40e400 mm). Speciﬁc activity was de-
termined for each individual reaction using the following formula: mm/
min¼ ([Rate (OD/min)/3] 1e4l). Statistical analysis was performed using
a Student t test on the raw data generated for control (glycosylated) andtest (deglycosylated) furin activity. The data are presented as the mean spe-
ciﬁc activity of three individual rates per assay  standard deviation.ResultsGLUCOSAMINE TREATMENT INTERFERES WITH ADAMTS5
ZYMOGEN PROCESSING AND AGGRECANASE ACTIVITYTo investigate a possible effect of glucosamine on
ADAMTS5, myc-tagged full-length ADAMTS5 (Fig. 1) was
transiently transfected in HEK293F cells and the molecular
species present in theCMwere evaluated bywestern blotting
with anti-myc-antibody and anti-propeptide antibody. The
medium of untreated cells showed the ADAMTS5 zymogen
(120 kDa) and mature ADAMTS5 (85 kDa) using anti-myc,
whereas the zymogen and cleaved 25 kDa propeptide were
recognized by anti-RP2 [Fig. 2(A)]. The relatively weak reac-
tivity of unprocessed ADAMTS5 with anti-RP2, compared to
anti-myc, likely reﬂects the stronger afﬁnity of the myc-anti-
body. The relatively low amount of the mature ADAMTS5 in
mediumpossibly reﬂects the previously reported observation
that heparin speciﬁcally enhances the detection of mature
ADAMTS5 inmedium of these cells. Thusmature ADAMTS5
may be sequestered in the ECMby ionic interactions. Mature
ADAMTS5 detected by anti-myc was decreased in the pres-
ence of 5 mM and 10 mM glucosamine with a corresponding
increase in the intact zymogen [Fig. 2(A), top panel]. Reduc-
tion of ADAMTS5 activation, as represented by a decrease in
proteolytically cleaved propeptide [detected by RP2,
459Osteoarthritis and Cartilage Vol. 18, No. 3Fig. 2(A), second panel from bottom] in CM, was observed
upon treatment with 5 and 10 mM glucosamine in both
HEK293F cells [Fig. 2(A, B)] and CHO-K1 cells (data not
shown).
Medium from ADAMTS5-expressing cells treated with
10 mM glucosamine contained signiﬁcantly less proteolytic
activity when cleavage of the Glu373eAla374 bond of aggre-
can core protein was compared to untreated cells, consistent
with reduced proADAMTS5 activation [Fig. 2(C)]. This
suggested that aggrecan proteolysis by ADAMTS5 was
profoundly affected by 10 mM glucosamine due to impaired
ADAMTS5 activation. Similarly, we found that constructs of
ADAMTS9 and ADAMTS20 expressed in HEK293F cells
also had reduced propeptide processing in the presence of
10 mMglucosamine (data not shown).We concluded that re-
duction of ADAMTS5-dependent aggrecan processing was
probably not a direct effect of glucosamine on ADAMTS5,
but an indirect effect on the processing mechanism.
Treatment of transfected HEK293F cells with 5 mM or
10 mM mannosamine also resulted in decreased removal
of the ADAMTS5 propeptide [Fig. 3(A)]. Because high
levels of hexosamines may have deleterious effects on
cells, we analyzed cell viability at the effective glucosamine
and mannosamine concentrations tested, as well as 25 mM
glucosamine. There was decreased cell viability in the pres-
ence of 25 mM glucosamine, as well as 5 mM and 10 mM
mannosamine [Fig. 3(B)]. Therefore, we primarily investi-
gated the effects of 10 mM glucosamine, since this did not
affect cell viability.GLUCOSAMINE AFFECTS ADAMTS5 ACTIVATION BY
INTERFERENCE WITH FURINPreviousworkhasestablished the roleof furin inADAMTSzy-
mogen processing, including ADAMTS59,24,27,28. GlucosamineFig. 5. Deglycosylation of puriﬁed recombinant furin reduces its activity. A.
ﬂuorescence (AMC liberation) vs time at 25C. Each curve represents the
furin preparation (HI¼ heat-inactivated). B. Activity of glycosylated vs deg
was measured at 10 min. The liberation of AMC by furin was signiﬁcan
C. Western blot of recombinant furin following treatmentis reported to affect transcription of many genes29,30, prompting
us toexaminewhether it affected furin transcription.Quantitative
RT-PCR demonstrated no signiﬁcant change in furin mRNA in
10 mM glucosamine-treated HEK293F cells [Fig. 4(A)]. Next,
we investigated the effect of glucosamine onendogenous cellu-
lar furin by western blot analysis. Furin is detected as a doublet
of the zymogen (90 kDa) and activated enzyme (85 kDa), in un-
treated HEK293F cells [Fig. 4(B)]. In the presence of 5 mM and
10 mMglucosamine, there was an increased intensity of a furin
species apparently co-migrating with active furin in untreated
cells [Fig. 4(B)]. However, since the activity of furin was clearly
reduced in thepresenceof10 mMglucosamine (Fig. 2),wecon-
cluded that this altered electrophoretic migration likely repre-
sented reduced furin glycosylation rather than increased
profurin conversion to active furin, consistent with a role for glu-
cosamine in inhibition of N-glycosylation20. The reduced furin
activity in the presence of glucosamine suggested that 85 kDa
furin species not only lacked glycosylation, but also failed to
be processed in the presence of 10 mM glucosamine. The en-
hanced furin immunoreactivity seen [Fig. 4(B)] could also result
from blockade of furin shedding from the cell surface but could
not be resolved by analysis of the CM of cells owing to the rela-
tively low levels present in medium. These data strongly sug-
gested that glucosamine impaired furin function via an effect
on post-translationalmodiﬁcation of furin, such as altered glyco-
sylation, decreased conversion to furin, decreased shedding or
a combination of these.REDUCED N-GLYCOSYLATION OF FURIN INHIBITS
ITS ACTIVITYTo resolve these various possibilities, we ﬁrst examined
whether mature furin was dependent on N-glycosylation
for its activity. Recombinant, puriﬁed, N-terminally His-
tagged human furin was treated with PNGaseF to eliminateKinetic data for two independent assays are plotted as a function of
mean kinetic data from triplicate reactions for each deglycosylated
lycosylated furin towards the ﬂuorogenic substrate Boc-RVRR-AMC
tly decreased by the removal of N-linked sugars with PNGaseF.
with PNGaseF, showing complete deglycosylation.
Fig. 6. Mutation of the N-glycosylation sites of furin inhibits its autoactivation. A. Schematic of human furin constructs used in the study depict-
ing their domain structure (key to various domains is at the bottom), predicted molecular weights, autocatalytic and C-terminal cleavage sites
and N-linked glycosylation sites. B. Detection of transiently expressed N-terminal FLAG-tagged WT-furin with or without dec-RVKR-CMK (dec-
RVKR-chloromethylketone) as well as FLAG-tagged Asn387Gln, Asn440Gln, Asn387þ440Gln furin mutants in HEK293F cells using anti-FLAG
M1 antibody. Note enhanced in-gel migration of the mutants, complete loss of activation of Asn387þ440Gln furin, and reduced activation of
Asn440Gln furin. Asn387þ440Gln furin migrates as a species intermediate in size between WT profurin and furin. C. Shed furin was detected
in the CM of the cells shown in B using a polyclonal anti-FLAG antibody, where similar relative migration of the various constructs is seen
as in cells, albeit with reduction of molecular mass owing to C-terminal processing. The active form of furin is not detected using this antibody.
D. Electrophoretic mobility of shed furin from transfected cells treated with or without 10 mM glucosamine was compared alongside the single
and double N-glycosylation mutants, suggestive of impaired N-glycosylation of WT furin in the presence of glucosamine. E. Western blot anal-
ysis of the samples shown in panel D was done following enzymatic deglycosylation with PNGaseF. Note that the 10 mM glucosamine-treated
furin and glycosylation mutant furin co-migrated with deglycosylated WT profurin, as well as with profurin from RVKR treated cells expressing
WT furin, indicating retention of the propeptide following 10 mM glucosamine treatment (compare with 6D). The identity of the 90 kDa band
seen upon RVKR treatment is not known. In panels B, C, and D, C indicates untransfected control.
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strate Boc-RVRR-AMC was signiﬁcantly impaired after
treatment with PNGaseF in two independent assays
[Fig. 5(A, B)]. Western blotting conﬁrmed complete deglyco-
sylation of the PNGaseF treated furin used in these assays
[Fig. 5(C)]. However, since the activity of mature furin was
only partially abolished by enzymatic deglycosylation, we
investigated the effect of glucosamine on cellular furin.
To better resolve the effect of glucosamine on profurin
conversion and shedding, we used plasmids for expression
of wild-type (WT) profurin or a profurin construct containing
a FLAG tag downstream of the autocatalytic processing sitein HEK293F cells [Fig. 6(A)]. Indeed, studies examining the
fate of furin have typically utilized such constructs since en-
dogenous furin is poorly detected31,32. Since profurin con-
version to the active form is an intrinsic, autocatalytic
process33, over-expression of these constructs by transient
transfection is valid for extrapolation of any observed
changes in activation status to endogenous furin. To better
visualize the active form of furin, we used the anti-FLAG M1
antibody, which is reported to have increased reactivity to
free N-terminal FLAG epitopes, since upon autoactivation,
the tagged construct will have a free N-terminal FLAG tag
[Fig. 6(A)]. N-terminal FLAG-tagged furin, or respective
Fig. 7. Glycosylation-deﬁcient furin mutants cannot process ADAMTS5 zymogen in CHO.RPE40 cells. A. WT furin and Asn387Gln-furin
increased ADAMTS5 propeptide processing above background, whereas Asn440Gln furin and Asn387þ440Gln furin did not rescue processing
(upper panel). GAPDH was used as a loading control (center panel). Intracellular levels of unprocessed ADAMTS5 Pro-Cat zymogen were
similar in each transfection (lower panel). B. Quantitation of ADAMTS5 propeptide in the CM (normalized to GAPDH) from the respective
transfections in A. These data were derived from three independent experiments and show statistically signiﬁcant reduction of activity of
Asn440Gln furin and Asn387þ440Gln furin (*P< 0.05 Student’s t test; error bars represent S.E.M).
461Osteoarthritis and Cartilage Vol. 18, No. 3mutants of the N-linked carbohydrate attachment sites
(Asn387Gln, Asn440Gln and Asn387þ440Gln) were trans-
fected into HEK293F cells. Cells transfected with FLAG-
tagged furin were also treated with or without 50 mM
dec-RVKR-CMK, a furin inhibitor, to inhibit autocatalytic
activation. Anti-FLAG M1 antibody detected furin species
at w90 kDa (profurin) and w85 kDa [zymogen and mature
furin respectively, Fig. 6(B)] in untreated cells. Cells treated
with dec-RVKR-CMK contained only furin zymogen
[Fig. 6(B)]. Asn387Gln and Asn440Gln mutants showed an
expected increase in electrophorectic mobility of both furin
species, but the relative position of the zymogen with re-
spect to the active form in each of these mutants was sim-
ilar to the WT furin [Fig. 6(B)]. Active furin was undetectable
in the Asn387þ440Gln mutant [Fig. 6(B)], suggesting that lack
of glycosylation at these two sites impaired furin autoactiva-
tion. The migration of Asn387þ440Gln profurin at a size inter-
mediate between WT profurin and active furin therefore
appears to reﬂect the net effect of reduced glycosylation
and impaired autoactivation, suggesting that the 85 kDa
band noted in cells treated with 10 mM glucosamine
[Fig. 4(B)] could be profurin deﬁcient in N-glycosylation,
and having reduced autoactivation. All transfected furin
constructs were shed from cells, and their reduced molecu-
lar mass relative to that observed for cellular furin [Fig. 6(C)]
was consistent with C-terminal processing of the mem-
brane-anchored enzyme26.
Since ablation of N-linkage sites and 10 mM glucosamine
each led to enhanced electrophoretic mobility of furin, we
considered whether glucosamine may hinder furin autoacti-
vation by interference with its glycosylation. Accordingly, we
compared the effect of glucosamine on FLAG-tagged furin
directly alongside the N-glycosylation mutants. Anti-FLAG
M1 antibody showed enhanced mobility of furin species
originating from the FLAG-tagged furin in the medium of
cells treated with 10 mM glucosamine, where two bands
were detected, the lower band migrated similarly to the
Asn387þ440Gln furin mutant [Fig. 6(D)]. The two molecular
species seen in the medium of 10 mM glucosamine-treated
cells were spaced more closely together than the twospecies present in medium of untreated cells [Fig. 6(D)].
This is suggestive of both species originating from the zy-
mogen with impaired activation and impaired glycosylation.
To resolve this, we enzymatically deglycosylated the CM
obtained from cells transfected with WT furin, furin mutants,
and 10 mM glucosamine-treated cells expressing WT furin.
Following enzymatic deglycosylation, furin from the medium
of 10 mM glucosamine-treated cells co-migrated with the
deglycosylated WT profurin and mutant profurin
[Fig. 6(E)]. This result establishes that treatment with
10 mM glucosamine severely compromises furin glycosyla-
tion. Since N-glycosylation is a co-translational event and
precedes furin autoactivation in the trans-Golgi, this would
argue that the observed lack of furin activation upon
10 mM glucosamine treatment could be secondary to im-
paired glycosylation of furin.
To determine whether elimination of one or more furin
N-linked glycosylation sites did indeed reduce furin activity,
CHO-RPE.40 cells that are deﬁcient in furin activity were
co-transfected withWT-furin (to eliminate potential functional
interference by a FLAG-tag), Asn387Gln-furin, Asn440Gln-
furin, or Asn387þ440Gln furin mutants, together with
ADAMTS5 Pro-Cat. A low level of baseline processing of
ADAMTS5Pro-Cat was seen in CHO-RPE.40 cells (presum-
ably mediated by other convertases), but was markedly in-
creased by co-expression of WT furin [Fig. 7(A)]. In
contrast, Asn440Gln furin and Asn387þ440Gln furin, but not
the Asn387Gln-furin mutant, showed statistically signiﬁcant
loss of ADAMTS5 Pro-Cat processing [Fig. 7(A, B)]. The
complete loss of activity of Asn387þ440Gln furin in regard to
propeptide excision [Fig. 7(A, B)] was consistent with the ob-
served lack of autocatalytic activation in this mutant
[Fig. 6(B)].
Discussion
Glucosamine is widely utilized as a presumed anabolic
agent, based on it being a precursor of cartilage glycosami-
noglycans34. Although patients often report symptomatic
beneﬁt from glucosamine or a combination of glucosamine
462 D. R. McCulloch et al.: Glucosamine and aggrecanase activationand chondroitin-sulfate, prospective randomized clinical tri-
als have not consistently supported a beneﬁcial effect35. On
the other hand, in vitro studies demonstrated suppression of
the catabolic response of cartilage explants and chondro-
cytes to retinoic acid and interleukin-1 in the presence of
glucosamine at similar concentrations used here13,16,18,19.
Inhibition of aggrecan catabolism in cartilage explants in
the presence of 5e10 mM glucosamine was reversible after
removal of glucosamine16. Glucosamine lacks a direct in-
hibitory effect on soluble aggrecanase activity, and was
only anti-catabolic in explant cultures undergoing a catabolic
stimulus16. Taken together, the previously published work
strongly suggested an effect of glucosamine on post-trans-
lational modiﬁcation of aggrecanases. Indeed, molecular
analysis of ADAMTS5 in this study demonstrates that
10 mM glucosamine impairs its activation by furin. Glucos-
amine is an inhibitor of N-linked glycosylation20, yet no con-
sistent effect was seen on electrophoretic mobility of
ADAMTS5. We found that glucosamine led to altered furin
migration on gels, as well as reduced activity upon elimina-
tion of N-linked carbohydrate in mature furin. Altered in-gel
furin migration and concomitant loss of processing activity
upon treatment of cells with 10 mM glucosamine leads us
to propose that impairment of furin glycosylation compro-
mises its conversion to active furin, which secondarily leads
to failed activation of ADAMTS zymogen.
The mechanisms uncovered in this study may provide in-
sights on several previously published observations regard-
ing the effect of glucosamine and mannosamine on
aggrecan catabolism in cartilage13,16,18,19. Suppression of
aggrecan catabolism by glucosamine, which we conﬁrmed
here, could be explained by the suppression of activation
of both major aggrecanases in cartilage explants by glucos-
amine, since removal of the ADAMTS4 and ADAMTS5 pro-
peptides is essential for their catalytic activity9,10. The lack
of N-glycosylation sites in ADAMTS4 argues that de-
creased ADAMTS415 or ADAMTS5 activation in the pres-
ence of glucosamine is not a consequence of altered
glycosylation of these ADAMTS proteases, and indeed,
there was no clear effect of glucosamine on migration of
ADAMTS5, which is N-glycosylated. It was previously dem-
onstrated that pretreatment of cartilage explants with glu-
cosamine did not confer a protective effect on the
subsequent exposure to IL-1, i.e., that the suppression of
catabolic activity in the presence of glucosamine was lost
after removal of glucosamine from the medium16. Since
the intracellular pool of glucosamine is rapidly depleted fol-
lowing its removal from the medium of cultured cells21 and
because furin is constitutively and continuously synthesized
and recycled by cells31, de novo furin production after re-
moval of glucosamine would allow ADAMTS processing to
occur. In addition, furin and/or other PCs secreted or shed
from cells after removal of glucosamine could activate
ADAMTS zymogens that were secreted unprocessed in
the presence of glucosamine and deposited in the ECM10.
The present studies contribute to understanding the pre-
viously documented protective effect of glucosamine on
cartilage catabolism in vitro in conjunction with other re-
ported effects of glucosamine such as increased transcrip-
tion of aggrecan, collagen II, and the aggrecanase inhibitor
TIMP329,36. Indeed, Chan et al.37, described suppression of
ADAMTS5 mRNA in bovine cartilage explants in response
to glucosamine, which we did not observe in HEK293F
cells. Thus glucosamine has the potential to suppress car-
tilage catabolism in several ways, albeit at doses that cur-
rently appear to be too high to be clinically relevant. The
effect described here is of broad biological signiﬁcance,since furin is responsible for molecular maturation of numer-
ous proproteins relevant to cartilage and OA, including pro-
hormones, growth factors, receptors, ECM proteins, and
proteases38. Treatment with glucosamine may be useful
for reversible reduction or suppression of maturation of
such substrates in cell culture, since we found there were
no changes in cell morphology or viability using 10 mM
glucosamine.
Glucosamine is well-tolerated and is not toxic orally, but
the serum and tissue concentrations achieved using the
typical dose of 1500 mg/day in short-term studies are far
lower than the levels we found to be required for blocking
ADAMTS5 activation34,39. Indeed the clinical trials testing
long-term glucosamine administration do not support a slow-
ing of arthritis progression40,41. Nevertheless, the effect we
report supports inhibition of aggrecanase zymogen activa-
tion as a potential therapeutic measure.Conﬂict of interest
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